2014
Discovery
Discovery of adenosine triphosphate (ATP) as a crucial inter-kingdom signaling molecule between the intestinal microbiota and host immune system.

2017
Patent
Patent filing in the US, Europe and other major markets on the apyrase (Apy) technology platform.

2017
StartCup Ticino
Second place as EXEAD project at StartCup Ticino conceived by CP Start-up (now Boldbrain), the yearly contest dedicated to Startups with the support of the Canton Ticino, Fondazione Agire , CP Start-up and Banca Stato.

2018
Incorporation
MicroVaccines SA is incorporated with the goal to move forward into clinical trials with the lead candidates.

2019
License
MV obtains the exclusive and global license of the Apy technology platform from IRB.

2020
Innosuisse coaching, new company name
MV is approved for core coaching by Innosuisse.

Having more indications and future applications, changed the too specific company name from MicroVaccines to MV BioTherapeutics.

2020
Fund raising
EU patent on Apy technology platform is granted as also in other countries.

ApyraMed - Biotherapeutic Technology

Proces Diagram